Stockreport

Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine

Insmed Incorporated  (INSM) 
Last insmed incorporated earnings: 4/30 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.insmed.com
PDF --As previously reported, study met primary endpoint of culture conversion (p --ALIS under FDA Priority Review with PDUFA action date of September 28, 2018-- BRIDGEWAT [Read more]